Botulinum Toxin and Percutaneous Needle Electrolysis for the Treatment of Chronic Masticatory Myalgia

Botulinum toxin type A (BTA) is applied in muscle hyperactivity disorders and injected into affected muscles, producing deep and persistent muscle relaxation. Several multidisciplinary groups investigated the treatment of temporomandibular disorders for several years, and there is currently some dat...

Descripción completa

Detalles Bibliográficos
Autores: González Pérez, Luis Miguel, Vera Martín, Ramón, Montes Latorre, Enrique, Torres Carranza, Eusebio, Infante Cossío, Pedro Antonio
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Universidad de Sevilla (US)
Repositorio:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/178593
Acceso en línea:https://hdl.handle.net/11441/178593
https://doi.org/10.3390/toxins15040278
Access Level:acceso abierto
Palabra clave:Long-term masticatory myalgia
Temporomandibular disorders
Pain management
Electromyography
Botulinum toxin type A
Percutaneous needle electrolysis
Randomized controlled trial
id ES_a6fef49dd48cfd2603f99b71be0a5ccf
oai_identifier_str oai:idus.us.es:11441/178593
network_acronym_str ES
network_name_str España
repository_id_str
spelling Botulinum Toxin and Percutaneous Needle Electrolysis for the Treatment of Chronic Masticatory MyalgiaGonzález Pérez, Luis MiguelVera Martín, RamónMontes Latorre, EnriqueTorres Carranza, EusebioInfante Cossío, Pedro AntonioLong-term masticatory myalgiaTemporomandibular disordersPain managementElectromyographyBotulinum toxin type APercutaneous needle electrolysisRandomized controlled trialBotulinum toxin type A (BTA) is applied in muscle hyperactivity disorders and injected into affected muscles, producing deep and persistent muscle relaxation. Several multidisciplinary groups investigated the treatment of temporomandibular disorders for several years, and there is currently some data on the beneficial effects of BTA in specific cases of chronic masticatory myalgia. Percutaneous needle electrolysis (PNE), which applies a low-intensity galvanic current to promote tissue regeneration, has been shown to be effective in reducing pain and improving masticatory function. The purpose of this study was to investigate the efficacy and safety of BTA and to assess whether its application in patients with localized masticatory myalgia can significantly reduce pain and improve function compared to a group treated with PNE. Fifty-two patients with long-term refractory masticatory myalgia were randomly assigned to two groups. The BTA group (n = 26) received a bilateral botulinum toxin injection and the PNE group (n = 26) received percutaneous electrolysis. The dose of BTA injected was 100 units distributed among the main primary masticatory muscles, and PNE was administered at 0.5 mA/3 s/3 consecutive times in a single session. Patient assessments were performed prior to treatment and one, two, and three months after treatment. The results revealed good therapeutic response in both groups. In the long term, both BTA and PNE showed high efficacy and safety in reducing pain and improving muscle function for the treatment of chronic masticatory myalgia. This improvement was sustained over a three-month period in both groups. Therefore, the use of BTA and PNE could be considered a valid and safe therapeutic alternative among the available options to treat refractory and localized masticatory myalgia when a better therapeutic response is expected as it demonstrated high efficacy.MDPICirugíaCTS142: Patología Morfolog. y Func. del Territorio Oral y Maxilofacial2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11441/178593https://doi.org/10.3390/toxins15040278reponame:idUS. Depósito de Investigación de la Universidad de Sevillainstname:Universidad de Sevilla (US)InglésToxins, 15 (4), 278.https://www.mdpi.com/2072-6651/15/4/278info:eu-repo/semantics/openAccessoai:idus.us.es:11441/1785932026-06-17T12:51:07Z
dc.title.none.fl_str_mv Botulinum Toxin and Percutaneous Needle Electrolysis for the Treatment of Chronic Masticatory Myalgia
title Botulinum Toxin and Percutaneous Needle Electrolysis for the Treatment of Chronic Masticatory Myalgia
spellingShingle Botulinum Toxin and Percutaneous Needle Electrolysis for the Treatment of Chronic Masticatory Myalgia
González Pérez, Luis Miguel
Long-term masticatory myalgia
Temporomandibular disorders
Pain management
Electromyography
Botulinum toxin type A
Percutaneous needle electrolysis
Randomized controlled trial
title_short Botulinum Toxin and Percutaneous Needle Electrolysis for the Treatment of Chronic Masticatory Myalgia
title_full Botulinum Toxin and Percutaneous Needle Electrolysis for the Treatment of Chronic Masticatory Myalgia
title_fullStr Botulinum Toxin and Percutaneous Needle Electrolysis for the Treatment of Chronic Masticatory Myalgia
title_full_unstemmed Botulinum Toxin and Percutaneous Needle Electrolysis for the Treatment of Chronic Masticatory Myalgia
title_sort Botulinum Toxin and Percutaneous Needle Electrolysis for the Treatment of Chronic Masticatory Myalgia
dc.creator.none.fl_str_mv González Pérez, Luis Miguel
Vera Martín, Ramón
Montes Latorre, Enrique
Torres Carranza, Eusebio
Infante Cossío, Pedro Antonio
author González Pérez, Luis Miguel
author_facet González Pérez, Luis Miguel
Vera Martín, Ramón
Montes Latorre, Enrique
Torres Carranza, Eusebio
Infante Cossío, Pedro Antonio
author_role author
author2 Vera Martín, Ramón
Montes Latorre, Enrique
Torres Carranza, Eusebio
Infante Cossío, Pedro Antonio
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Cirugía
CTS142: Patología Morfolog. y Func. del Territorio Oral y Maxilofacial
dc.subject.none.fl_str_mv Long-term masticatory myalgia
Temporomandibular disorders
Pain management
Electromyography
Botulinum toxin type A
Percutaneous needle electrolysis
Randomized controlled trial
topic Long-term masticatory myalgia
Temporomandibular disorders
Pain management
Electromyography
Botulinum toxin type A
Percutaneous needle electrolysis
Randomized controlled trial
description Botulinum toxin type A (BTA) is applied in muscle hyperactivity disorders and injected into affected muscles, producing deep and persistent muscle relaxation. Several multidisciplinary groups investigated the treatment of temporomandibular disorders for several years, and there is currently some data on the beneficial effects of BTA in specific cases of chronic masticatory myalgia. Percutaneous needle electrolysis (PNE), which applies a low-intensity galvanic current to promote tissue regeneration, has been shown to be effective in reducing pain and improving masticatory function. The purpose of this study was to investigate the efficacy and safety of BTA and to assess whether its application in patients with localized masticatory myalgia can significantly reduce pain and improve function compared to a group treated with PNE. Fifty-two patients with long-term refractory masticatory myalgia were randomly assigned to two groups. The BTA group (n = 26) received a bilateral botulinum toxin injection and the PNE group (n = 26) received percutaneous electrolysis. The dose of BTA injected was 100 units distributed among the main primary masticatory muscles, and PNE was administered at 0.5 mA/3 s/3 consecutive times in a single session. Patient assessments were performed prior to treatment and one, two, and three months after treatment. The results revealed good therapeutic response in both groups. In the long term, both BTA and PNE showed high efficacy and safety in reducing pain and improving muscle function for the treatment of chronic masticatory myalgia. This improvement was sustained over a three-month period in both groups. Therefore, the use of BTA and PNE could be considered a valid and safe therapeutic alternative among the available options to treat refractory and localized masticatory myalgia when a better therapeutic response is expected as it demonstrated high efficacy.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11441/178593
https://doi.org/10.3390/toxins15040278
url https://hdl.handle.net/11441/178593
https://doi.org/10.3390/toxins15040278
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Toxins, 15 (4), 278.
https://www.mdpi.com/2072-6651/15/4/278
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:idUS. Depósito de Investigación de la Universidad de Sevilla
instname:Universidad de Sevilla (US)
instname_str Universidad de Sevilla (US)
reponame_str idUS. Depósito de Investigación de la Universidad de Sevilla
collection idUS. Depósito de Investigación de la Universidad de Sevilla
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869415742233903104
score 15.811543

Similares en LA Referencia